share_log

康弘药业:北京市通商(深圳)律师事务所关于成都康弘药业集团股份有限公司2022年股票增值权激励计划第二个行权期行权条件成就的法律意见书

Kanghong Pharmaceutical: Legal Opinion of Beijing Commerce (Shenzhen) Law Firm on the Achievement of the Enforcement Conditions for the Second Exercise Period of the 2022 Stock Value-added Rights Incentive Plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd.

SZSI ·  Oct 25

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.